Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Fatty Liver | Research

A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease

Authors: Yvelise Ferro, Roberta Pujia, Elisa Mazza, Lidia Lascala, Oscar Lodari, Samantha Maurotti, Arturo Pujia, Tiziana Montalcini

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Currently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, S-adenosyl-l-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease.

Methods

A total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus®) containing a combination of natural bioactive components for 12 weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12 weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention.

Results

After adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum γGT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (− 34 ± 5 dB/m vs. − 20 ± 5 dB/m, respectively; p = 0.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men.

Conclusion

Our results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12 weeks in individuals with hepatic steatosis.
Trial registration ISRCTN, ISRCTN70887063. Registered 03 August 2021—retrospectively registered, https://​doi.​org/​10.​1186/​ISRCTN70887063
Appendix
Available only for authorised users
Literature
1.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.PubMedCrossRef
2.
3.
4.
5.
Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.PubMedCrossRef
6.
Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology. 2018;68:2230–8.PubMedCrossRef
7.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.PubMedCrossRef
8.
Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, et al. Modelling NAFLD disease burden in four Asian regions-2019–2030. Aliment Pharmacol Ther. 2020;51:801–11.PubMedPubMedCentralCrossRef
9.
Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern Med. 2019;179:1262–71.PubMedPubMedCentralCrossRef
10.
11.
Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou YD, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci. 2019;15:265–76.PubMedPubMedCentralCrossRef
12.
13.
14.
Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, et al. The role of curcumin in liver diseases. Arch Med Sci. 2019;15:1608–20.PubMedCrossRef
15.
16.
Musolino V, Gliozzi M, Bombardelli E, Nucera S, Carresi C, Maiuolo J, et al. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. J Tradit Complement Med. 2020;10(3):268–74.PubMedPubMedCentralCrossRef
17.
Panahi Y, Kianpour P, Mohtashami R, Atkin SL, Butler AE, Jafari R, et al. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial. Phytother Res. 2018;32(7):1382–7.PubMedCrossRef
18.
Lee M, Kim D, Park SJ, Kim KS, Park GD, Kim OK, et al. Artichoke extract directly suppresses inflammation and apoptosis in hepatocytes during the development of non-alcoholic fatty liver disease. J Med Food. 2021;24:1058–67.PubMedCrossRef
19.
20.
Verma PC, Basu V, Gupta V, Saxena G, Rahman LU. Pharmacology and chemistry of a potent hepatoprotective compound picroliv isolated from the roots and Rhizomes of Picrorhiza kurroa royle ex benth. (kutki). Curr Pharm Biotechnol. 2009;10:641–9.PubMedCrossRef
21.
Benić MS, Nežić L, Vujić-Aleksić V, Mititelu-Tartau L. Novel therapies for the treatment of drug-induced liver injury: a systematic review. Front Pharmacol. 2022;12:785–90.CrossRef
22.
Khanna AK, Chander R, Kapoor NK, Dhawan BN. Hypolipedaemic activity of picroliv in albino rats. Phytother Res. 1994;8:403–7.CrossRef
23.
Joy KL, Kuttan R. Anti-diabetic activity of Picrorrhiza kurroa extract. J Ethnopharmacol. 1999;67:143–8.PubMedCrossRef
24.
Choi Y, Abdelmegeed MA, Song BJ. Preventive effects of indole-3-carbinol against alcohol-induced liver injury in mice via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms: role of gut-liver-adipose tissue axis. J Nutr Biochem. 2018;55:12–25.PubMedCrossRef
25.
Choi Y, Yanagawa Y, Kim S, Park T. Involvement of SIRT1-AMPK signaling in the protective action of indole-3-carbinol against hepatic steatosis in mice fed a high-fat diet. J Nutr Biochem. 2013;24:1393–400.PubMedCrossRef
26.
Ji Y, Gao Y, Chen H, Yin Y, Zhang W. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients. 2019;11:2062.PubMedCentralCrossRef
27.
Hashem A, Shastri Y, Al Otaibi M, Buchel E, Saleh H, Ahmad R, et al. Expert opinion on the management of non-alcoholic fatty liver disease (NAFLD) in the Middle East with a focus on the use of silymarin. Gastroenterol Insights. 2021;12:155–65.CrossRef
28.
Salvoza N, Giraudi PJ, Tiribelli C, Rosso N. Natural compounds for counteracting nonalcoholic fatty liver disease (NAFLD): advantages and limitations of the suggested candidates. Int J Mol Sci. 2022;23:2764.PubMedPubMedCentralCrossRef
29.
Sun R, Xu D, Wei Q, Zhang B, Aa J, Wang G, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020;123: 109721.PubMedCrossRef
30.
Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-κB pathway. Dig Dis Sci. 2018;63:3398–408.PubMedCrossRef
31.
Liu X, Sun R, Li Z, Xiao R, Lv P, Sun X, et al. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch Biochem Biophys. 2021;711: 109019.PubMedCrossRef
32.
Kwon EY, Jung UJ, Park T, Yun JW, Choi MS. Luteolin attenuates hepatic steatosis and insulin resistance through the interplay between the liver and adipose tissue in mice with diet-induced obesity. Diabetes. 2015;64:1658–69.PubMedCrossRef
33.
Jia Y, Wu C, Kim J, Kim B, Lee SJ. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt. J Nutr Biochem. 2016;28:9–18.PubMedCrossRef
34.
Lim SH, Lee HS, Lee CH, Choi CI. Pharmacological activity of Garcinia indica (kokum): an updated review. Pharmaceuticals (Basel). 2021;14:1338.CrossRef
35.
36.
Chung MY, Shin EJ, Choi HK, Kim SH, Sung MJ, Park JH, et al. Schisandra chinensis berry extract protects against steatosis by inhibiting histone acetylation in oleic acid-treated HepG2 cells and in the livers of diet-induced obese mice. Nutr Res. 2017;46:1–10.PubMedCrossRef
37.
Wong SK, Chin KY, Ahmad F, Ima-Nirwana S. Regulation of inflammatory response and oxidative stress by tocotrienol in a rat model of non-alcoholic fatty liver disease. J Funct Foods. 2020;74: 104209.CrossRef
38.
Alomar M, Al-attar A. Effect of basil leaves extract on liver fibrosis induced by thioacetamide in male rats. Int J Pharmacol. 2019;15:478–85.CrossRef
39.
Jamshidi N, Cohen MM. The clinical efficacy and safety of tulsi in humans: a systematic review of the literature. Evid Based Complement Alternat Med. 2017;2017:9217567.PubMedPubMedCentralCrossRef
40.
Di Napoli A, Zucchetti P. A comprehensive review of the benefits of Taraxacum officinale on human health. Bull Natl Res Cent. 2021;45:110.CrossRef
41.
Shelly CL. Dysregulation of glutathione synthesis in liver disease. Liver Res. 2020;4:64–73.CrossRef
42.
Guo T, Chang L, Xiao Y, Liu Q. S-Adenosyl-l-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0122124.PubMedPubMedCentralCrossRef
43.
Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17:96.PubMedPubMedCentralCrossRef
44.
Mazza E, Fava A, Ferro Y, Rotundo S, Romeo S, Bosco D, et al. Effect of the replacement of dietary vegetable oils with a low dose of extravirgin olive oil in the mediterranean diet on cognitive functions in the elderly. J Transl Med. 2018;16:10.PubMedPubMedCentralCrossRef
45.
Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. Eur J Clin Nutr. 2010;64:2–5.PubMedCrossRef
46.
Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the cardiovascular health study. Arch Intern Med. 1999;59:1339–47.CrossRef
47.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
48.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022–30.PubMedCrossRef
49.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMedCrossRef
50.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
51.
Matsuura T, Kaneko H, Takayama K, Shibata R, Kataoka K, Ito S, et al. Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration. BMC Ophthalmol. 2020;20:56.PubMedPubMedCentralCrossRef
52.
Shah P, Modi HA. Comparative study of DPPH, ABTS and FRAP assays for determination of antioxidant activity. Int J ResAppl Sci Eng Technol. 2015;3:636–41.
53.
Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Faliva M, Perna S, et al. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. Eur J Gastroenterol Hepatol. 2015;27:305–12.PubMedCrossRef
54.
55.
Caldwell JL, Chambers KA, Moore DC, Yates CR, Bloomer RJ. Ingredient dosing within dietary supplements: are you getting enough? Acta Sci Nutr Health. 2018;2:54–63.
56.
57.
Méndez L, Medina I. Polyphenols and fish oils for improving metabolic health: a revision of the recent evidence for their combined nutraceutical effects. Molecules. 2021;26:2438.PubMedPubMedCentralCrossRef
58.
Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98:27i–33i.PubMedCrossRef
59.
Rodríguez-Cruz M, Serna DS. Nutrigenomics of ω-3 fatty acids: regulators of the master transcription factors. Nutrition. 2017;41:90–6.PubMedCrossRef
60.
Van Name MA, Savoye M, Chick JM, Galuppo BT, Feldstein AE, Pierpont B, et al. A low ω-6 to ω-3 PUFA ratio (n-6:n-3 PUFA) diet to treat fatty liver disease in obese youth. J Nutr. 2020;150:2314–21.PubMedPubMedCentralCrossRef
61.
Goyal SN, Prajapati CP, Gore PR, Patil CR, Mahajan UB, Sharma C, et al. Therapeutic potential and pharmaceutical development of thymoquinone: a multitargeted molecule of natural origin. Front Pharmacol. 2017;8:656.PubMedPubMedCentralCrossRef
62.
Ding L, Li J, Song B, Xiao X, Zhang B, Qi M, et al. Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol Appl Pharmacol. 2016;304:99–109.PubMedCrossRef
63.
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol. 2016;68:223–9.PubMedCrossRef
64.
Selmanovic S, Beganlic A, Salihefendic N, Ljuca F, Softic A, Smajic E. Therapeutic effects of curcumin on ultrasonic morphological characteristics of liver in patients with metabolic syndrome. Acta Inform Med. 2017;25:169–74.PubMedPubMedCentralCrossRef
65.
66.
Riva A, Petrangolini G, Allegrini P, Perna S, Giacosa A, Peroni G, et al. Artichoke and bergamot phytosome alliance: a randomized double blind clinical trial in mild hypercholesterolemia. Nutrients. 2021;14:108.PubMedPubMedCentralCrossRef
67.
Panahi Y, Kianpour P, Mohtashami R, Atkin SL, Butler AE, Jafari R, et al. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial. Phytother Res. 2018;32:1382–7.PubMedCrossRef
68.
Bhosale V. Incidence of hepatotoxicity in Indian patients receiving standard multidrug anti-tubercular therapy without risk factors. Clin Epidemiol Glob Health. 2013;1:58.
69.
Ulasoglu C, Enc FY, Kaya E, Yilmaz Y. Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels. J Gastrointest Liver Dis. 2019;28:427–31.CrossRef
70.
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.PubMedCrossRef
71.
Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796–803.PubMedCrossRef
72.
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457–69.PubMedCrossRef
73.
Salvoza NC, Giraudi PJ, Tiribelli C, Rosso N. Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. Explor Med. 2020;1:51–74.CrossRef
74.
Cvitanović Tomaš T, Urlep Ž, Moškon M, Mraz M, Rozman D. LiverSex computational model: sexual aspects in hepatic metabolism and abnormalities. Front Physiol. 2018;9:360.PubMedPubMedCentralCrossRef
75.
Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12:611–20.PubMedCrossRef
76.
Yoshida M, Harada N, Yoshida K, Nakagawa T, Shimohata T, Mawatari K, et al. High density lipoprotein inhibits the activation of sterol regulatory element-binding protein-1 in cultured cells. FEBS Lett. 2010;584:1217–22.PubMedCrossRef
77.
Putignano P, Miraglia N. New perspectives of S-adenosylmethionine (SAMe) applications to attenuate fatty acid-induced steatosis and oxidative stress in hepatic and endothelial cells. Molecules. 2020;25:4237.PubMedCentralCrossRef
78.
Baldini F, Portincasa P, Grasselli E, Damonte G, Salis A, Bonomo M, et al. Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865: 158586.PubMedCrossRef
79.
Yang B, Zhou Y, Wu M, Li X, Mai K, Ai Q. ω-6 Polyunsaturated fatty acids (linoleic acid) activate both autophagy and antioxidation in a synergistic feedback loop via TOR-dependent and TOR-independent signaling pathways. Cell Death Dis. 2020;11:607.PubMedPubMedCentralCrossRef
80.
Parafati M, Lascala A, Morittu VM, Trimboli F, Rizzuto A, Brunelli E, et al. Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome. J Nutr Biochem. 2015;26:938–48.PubMedCrossRef
81.
Nakajima T, Yang Y, Lu Y, Kamijo Y, Yamada Y, Nakamura K, et al. Decreased fatty acid β-oxidation is the main cause of fatty liver induced by polyunsaturated fatty acid deficiency in mice. Tohoku J Exp Med. 2017;242:229–39.PubMedCrossRef
82.
Constantin RP, do Nascimento GS, Constantin RP, Salgueiro CL, Bracht A, Ishii-Iwamoto EL, et al. Citrus flavanones affect hepatic fatty acid oxidation in rats by acting as prooxidant agents. Biomed Res Int. 2013;2013: 342973.PubMedPubMedCentralCrossRef
83.
Panahi Y, Valizadegan G, Ahamdi N, Ganjali S, Majeed M, Sahebkar A. Curcuminoids plus piperine improve nonalcoholic fatty liver disease: a clinical trial. J Cell Biochem. 2019;120:15989–96.PubMedCrossRef
84.
Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med. 2012;52:1658–65.PubMedCrossRef
85.
Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res. 2016;30:1540–8.PubMedCrossRef
86.
Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149–58.PubMedCrossRef
87.
Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475–85.PubMedPubMedCentralCrossRef
88.
Collins LM, Graham JW. The effect of the timing and spacing of observations in longitudinal studies of tobacco and other drug use: temporal design considerations. Drug Alcohol Depend. 2002;68:S85–96.PubMedCrossRef
89.
Raudenbush SW, Xiao-Feng L. Effects of study duration, frequency of observation, and sample size on power in studies of group differences in polynomial change. Psychol Methods. 2001;6:387–401.PubMedCrossRef
90.
91.
Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923–34.PubMedPubMedCentralCrossRef
92.
93.
94.
Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials. BJOG. 2018;125:1716.PubMedPubMedCentralCrossRef
Metadata
Title
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Authors
Yvelise Ferro
Roberta Pujia
Elisa Mazza
Lidia Lascala
Oscar Lodari
Samantha Maurotti
Arturo Pujia
Tiziana Montalcini
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Fatty Liver
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03579-1

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

SPTBN1 abrogates renal clear cell carcinoma progression via glycolysis reprogramming in a GPT2-dependent manner

Research

Low potassium disrupt intestinal barrier and result in bacterial translocation

Research

Pan-cancer quantitation of epithelial-mesenchymal transition dynamics using parallel reaction monitoring-based targeted proteomics approach

Research

A comparison of health-related factors between patients diagnosed with ME/CFS and patients with a related symptom picture but no ME/CFS diagnosis: a cross-sectional exploratory study

Research

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response

Research

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits